Dr Reddy’s And Perrigo Capitalize On Voltaren Switch
‘First Store Brand ANDA’ Of OTC Diclofenac Gel Launched
Executive Summary
Seven months after GlaxoSmithKline’s Voltaren Arthritis Pain (diclofenac sodium) 1% topical gel was switched to non-prescription status in the US, two companies have begun shipping equivalent OTC versions to retailers.
You may also be interested in...
Dr Reddy’s Enters OTC Eyecare Space
Dr Reddy’s has announced the launch of its OTC versions of Pataday olopatadine solution in the US. The firm’s entry into the OTC eyecare space follows other OTC launches of rivals to Voltaren and Nicorette earlier this year.
Dr Reddy’s Enters OTC Eyecare Space
Dr Reddy’s has announced the launch of its OTC versions of Pataday olopatadine solution in the US. The firm’s entry into the OTC eyecare space follows other OTC launches of rivals to Voltaren and Nicorette earlier this year.
Takeda Pens Mid-Trial Settlement To Dismiss US Colcrys Antitrust Suit
Japanese originator Takeda has agreed to settle two-year-old anticompetitive claims lodged by wholesalers in the US that it conspired with several generics manufacturers to maintain supracompetitive pricing for its Colcrys branded treatment for gout.